These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 15780796

  • 1. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW, Verma S, Weisel RD, Li RK.
    Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
    [Abstract] [Full Text] [Related]

  • 2. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
    Vanhoutte D, Heymans S.
    J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 4. Extracellular degradative pathways in myocardial remodeling and progression to heart failure.
    Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC.
    J Card Fail; 2002 Dec 02; 8(6 Suppl):S332-8. PubMed ID: 12555141
    [Abstract] [Full Text] [Related]

  • 5. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ, Zhang X, Zhu WL, Huang Y.
    Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324
    [Abstract] [Full Text] [Related]

  • 6. Novel approaches to retard ventricular remodeling in heart failure.
    Spinale FG.
    Eur J Heart Fail; 1999 Mar 27; 1(1):17-23. PubMed ID: 10937974
    [Abstract] [Full Text] [Related]

  • 7. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG.
    Physiol Rev; 2007 Oct 27; 87(4):1285-342. PubMed ID: 17928585
    [Abstract] [Full Text] [Related]

  • 8. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
    Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J.
    J Am Coll Cardiol; 2004 Oct 19; 44(8):1609-18. PubMed ID: 15489093
    [Abstract] [Full Text] [Related]

  • 9. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S, Lijnen HR.
    Cardiovasc Res; 2006 Feb 15; 69(3):585-94. PubMed ID: 16426591
    [Abstract] [Full Text] [Related]

  • 10. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 11. Cardiac remodeling and failure: from molecules to man (Part III).
    Fedak PW, Verma S, Weisel RD, Skrtic M, Li RK.
    Cardiovasc Pathol; 2005 Feb 15; 14(3):109-19. PubMed ID: 15914295
    [Abstract] [Full Text] [Related]

  • 12. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 15; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 13. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
    Vanhoutte D, Schellings M, Pinto Y, Heymans S.
    Cardiovasc Res; 2006 Feb 15; 69(3):604-13. PubMed ID: 16360129
    [Abstract] [Full Text] [Related]

  • 14. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z.
    Circulation; 2011 Nov 08; 124(19):2094-105. PubMed ID: 21986284
    [Abstract] [Full Text] [Related]

  • 15. Extracellular matrix dynamics in heart failure: a prospect for gene therapy.
    Tyagi SC.
    J Cell Biochem; 1998 Mar 15; 68(4):403-10. PubMed ID: 9493904
    [Abstract] [Full Text] [Related]

  • 16. Cardiac remodeling and failure: from molecules to man (Part I).
    Fedak PW, Verma S, Weisel RD, Li RK.
    Cardiovasc Pathol; 2005 Mar 15; 14(1):1-11. PubMed ID: 15710285
    [Abstract] [Full Text] [Related]

  • 17. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
    Janicki JS, Brower GL, Gardner JD, Forman MF, Stewart JA, Murray DB, Chancey AL.
    Cardiovasc Res; 2006 Feb 15; 69(3):657-65. PubMed ID: 16376324
    [Abstract] [Full Text] [Related]

  • 18. Roles of MMP/TIMP in regulating matrix swelling and cell migration during chick corneal development.
    Huh MI, Lee YM, Seo SK, Kang BS, Chang Y, Lee YS, Fini ME, Kang SS, Jung JC.
    J Cell Biochem; 2007 Aug 01; 101(5):1222-37. PubMed ID: 17295208
    [Abstract] [Full Text] [Related]

  • 19. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG.
    Circ Res; 2002 Mar 22; 90(5):520-30. PubMed ID: 11909815
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.